Durata Therapeutics, Inc. Announces Preclinical Data Supporting Clinical Development of Dalbavancin for the Treatment of Pneumonia

Published: Oct 19, 2012

SAN DIEGO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced in vitro study data that could help support a clinical development program to investigate its lead product candidate, dalbavancin, for the treatment of pneumonia. In this study, lung surfactant did not have a significant impact on the in vitro susceptibility of Staphylococcus aureus and Streptococcus pneumoniae to dalbavancin.

Back to news